Oticon Adds Zeal, Intent, and Verit Hearing Aids to VA Contract
The new additions include an in-the-ear rechargeable, a flexible miniBTE R, and a zinc-air miniRITE T model designed for government services audiologists and their patients.
The new additions include an in-the-ear rechargeable, a flexible miniBTE R, and a zinc-air miniRITE T model designed for government services audiologists and their patients.
With several completely implantable CIs in development, a new device choice for patients with severe-to-profound hearing loss is on the horizon.
The in-the-ear hearing aid has now received five industry awards for its design and performance since its August 2025 launch.
In a pivotal trial, 42% of participants achieved normal hearing using the gene therapy indicated for pediatric and adult patients with severe-to-profound hearing loss due to biallelic OTOF gene variants.
Developed by the National Acoustic Laboratories, the system builds on NAL-NL2 and is designed for more precise, personalized hearing aid fittings.
The program is designed to help audiologists offer hearing aid jewelry to patients without carrying inventory risk.